Share

    


Home / Search Results

Search Results

You searched for:

An overview of the modern health care workforce reveals a concerning disparity in the amount of African American medical professionals.
ACCCBuzz spoke with Erika Siegrist at Luminis Health Research Institute to learn more about how technology has helped expand patient access to cancer clinical trials.
At the 2023 National Minority Quality Forum Summit on Health Disparities and Spring Health Braintrust, panelists discussed strategies that can be implemented to improve diversity in clinical trials.
Lankenau Medical Center operationalized this joint ASCO-ACCC implicit bias aimed at ensuring patients with cancer in underrepresented groups have equitable access to care and clinical trials.
November 13 to 19 is dedicated to National Nurse Practitioner Week, and the Association of Community Cancer Centers (ACCC) is taking this opportunity to recognize its nurse practitioner (NP) members—highlighting the work NPs do to improve access to care, the patient and clinician experience, and patient outcomes.
The ACCC 39th National Oncology Conference opened with two pre-conferences, covering financial advocacy in oncology and the future of cancer care. Learn what care delivery may look like in 2040 and how ACCC is supporting cancer programs and practices through its Financial Advocacy Network.
June 16 to 22 is National Black Family Cancer Awareness Week—a week dedicated to increase awareness of the importance of clinical trial participation and specimen donations for cancer research among Black Americans. Learn what ACCC is doing to address health disparities for all underserved populations across America.
ACCC has partnered with several of its oncology state societies to establish the Appalachian Community Cancer Alliance—a key effort to address disparities in cancer screening and care delivery in the region.
The second post in a three-blog series, ACCCBuzz shares how Carolina Blood and Cancer Care Associates' NOLA initiative is addressing access to care, clinical trials, biomarker testing, and more.
Carolina Blood and Cancer Care Associate's No One Left Alone (or NOLA) initiative is a multi-phase pilot program aimed at lessening disparities in cancer care in three key areas: care access, biomarker testing, and clinical trials.
Under ACORI, ACCC helps community oncology programs access the tools, knowledge sharing, effective practices, and peer mentorships that can increase their ability to offer clinical trials.
Learn the 10 feasible and impactful “how-tos” Summit participants identified within three domains—care coordination and communication, clinical trials, and acknowledging and mitigating implicit bias.
In 2021, ACCC launched the ACCC Community Oncology Research Institute (ACORI), which builds on ACCC’s mission to achieve equitable cancer care for all patients by forming key community partnerships. As part of this mission, ACCC hosted the ACORI Call to Action Summit, a two-day virtual event held September 13-14, 2021, to garner participant feedback and guide the future of the institute.
Beginning January 2022, CMS will be required to cover for Medicaid patients the routine costs associated with participating in clinical trials. Learn what states and provider organizations can do to leverage this mandate to address barriers to care in the community and reduce inequities in clinical trial participation.
One of the ways in which community oncology is helping to close gaps in cancer research is through participation in the National Cancer Institute Community Oncology Research Program clinical trials. The Lahey Health Cancer Institute, a part of the Beth Israel Lahey Health System, continues to expand access to clinical trials and, in particular, the NCI National Clinical Trials Network into the community …
One important step toward supporting the health of Indigenous Peoples was the opening of the Center for Indigenous Cancer Research (CICR) at Roswell Park Comprehensive Cancer Center in January 2020. Its mission: to reduce the impact of cancer on Indigenous communities regionally, nationally, and internationally.
Older adults with cancer are consistently precluded from participating in clinical trials for promising new treatments. A multi-pronged approach is required to ensure trials are developed for all patients, including paying specific attention to inclusion/exclusion criteria and creating clinically meaningful endpoints that can enhance enrollment efforts in underserved populations.
Poor access to care among AYA patients is not only evident in low clinical trial enrollment. The struggle to access much-needed care continues when treatment concludes. Most AYA cancer survivors must learn to navigate follow-up medical care on their own.
This is the story of how a large independent practice in northwest Arkansas has nurtured its research program over several decades and is now able to offer patients access to phase I, II, and III trials close to home and their families.
Improving patient access to clinical trials has long been a vexing issue for clinicians and patient advocates. Although trials are the backbone of cancer research, participation rates have remained unchanged in recent decades. As a result, more attention is being paid to the lack of diversity in clinical trial populations. The National Coalition for Cancer Survivorship (NCCS) held its 2019 Cancer Policy …